Dr. Takeshima@Web

  講演会動画視聴    講演会では、AIによる同時翻訳を使用し、視聴者の理解を補助しました。 おかしな訳も少なくありませんでしたが、ある程度は役にたっていたと思います。 

 

モンゴル神経学会から招待いただいて、頭痛についてレクチャーしました。 参加者は熱心に聴講してくれました。よい経験でした。  

    Hirata K, Takeshima T, Imai N, Igarashi H, Shiosakai M, Inage M, et al.  A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.  Expert Opinion on Drug Safety. 2022:1-8.  

    Kikui S, Chen Y, Ikeda K, Hasebe M, Asao K, Takeshima T.  Comorbidities in patients with migraine in Japan: a cross-sectional study using data from National Health and Wellness Survey.  BMJ Open. 2022;12(11):e065787. https://www.ncbi.nlm.nih.gov/pubmed/36450434 https://bmjopen.bmj.com/content/bmjopen/12/11/e065787.full.pdf 2022/12/01

 五十嵐久佳先生が、頭痛医療と社会貢献をテーマに第50回日本頭痛学会総会を開催されました。オンサイトでも多くの参加者があり、活気にみちた総会でした。竹島はシンポジウムの座長、一般演題口演、スポンサードセミナー座長などを務めました。当院から、あるいは共同研究の発表はシンポジウム1題、一般演題8題でした。   シンポジウム     一般演題     スポンサードセミナー           

  Takeshima T, Komori M, Tanji Y, Ozeki A, Tatsuoka Y.  Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.  Adv Ther. 2022;39(11):5274-88. https://www.ncbi.nlm.nih.gov/pubmed/36138260 2022/09/23

 Sakai F, Hirata K, Igarashi H, Takeshima T, Nakayama T, Sano H, et al.  A study to investigate the prevalence of headache disorders and migraine among people registered in a health insurance association in Japan.  J Headache Pain. 2022;23(1):70. https://www.ncbi.nlm.nih.gov/pubmed/35733104 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219245/pdf/10194_2022_Article_1439.pdf 2022/06/23  

 英文原著 1) Takeshima T , Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.  Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache 2021;61(6): 927-935. https://www.ncbi.nlm.nih.gov/pubmed/34153117 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361926/pdf/HEAD-61-927.pdf   2)  Hirata K, Sakai F, Takeshima T , Imai N, Matsumori Y, Yoshida R, Numachi Y, Peng C, Mikol DD, Cheng S. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. J Headache Pain. 2021;22(1): 110. https://www.ncbi.nlm.nih.gov/pubmed/34537006 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449906/pdf/10194_2021_Article_1313.pdf 3)  Hirata K, Ueda K, Komori M, Zagar AJ, Selzler KJ, Nelson AM, Han Y, Jaffe DH, Matsumori Y, Takeshim...

      Danno D, Wolf J, Ishizaki K, Kikui S, Hirata K, Takeshima T.  Cranial autonomic symptoms in migraine are related to central sensitization: a prospective study of 164 migraine patients at a tertiary headache center.  BMC Neurol. 2022;22(1):89. https://www.ncbi.nlm.nih.gov/pubmed/35287610 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919542/pdf/12883_2022_Article_2610.pdf 2022/03/16

  Oda I, Danno D, Saigoh K, Wolf J, Kawashita N, Hirano M, Samukawa M,Kitamura S, Kikui S,Takeshima T, Mitsui Y,Kusunoki S,Nagai Y Hemiplegic migraine type 2 with new mutation of the ATP1A2 gene in Japanese cases.  Neurosci Res. 2022;180:83-9. https://www.ncbi.nlm.nih.gov/pubmed/35257835 2022/03/09

   Hirata K, Takeshima T, Sakai F, Imai N, Matsumori Y, Tatsuoka Y, et al.  Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.  Brain Behav. 2022;12(3):e2526. https://www.ncbi.nlm.nih.gov/pubmed/35201674 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933787/pdf/BRB3-12-e2526.pdf 2022/02/25

      Takeshima T , Nakai M, Shibasaki Y, Ishida M, Kim BK, Ning X, et al.  Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.  J Headache Pain. 2022;23(1):24. https://www.ncbi.nlm.nih.gov/pubmed/35139816 2022/02/11

    Takahashi M, Shimokawa T, Koh J, Takeshima T, Yamashita H, Kajimoto Y, et al.  Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan.  J Neurol Sci. 2022;432:120078. https://www.ncbi.nlm.nih.gov/pubmed/34923334 2021/12/20